NEXUS AG

NXU

Equity

ISIN DE0005220909 / Valor 1099292

Xetra (2025-03-14)

EUR 69.00-0.72%

NEXUS AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

NEXUS AG is a European company specializing in the development of innovative software solutions for the healthcare sector. Their product offerings include a clinical information system (NEXUS / KIS) and integrated diagnostic modules (NEXUS / DIS), designed to meet the wide-ranging functional requirements of hospitals, psychiatric institutions, rehabilitation, and diagnostic centers. The company focuses on creating user-friendly process support tools that enhance efficiency and safety in patient care. With over 250,000 daily users, including doctors, nurses, and administrative staff across various healthcare facilities, NEXUS AG emphasizes close customer relationships and localized support. Employing approximately 1,700 staff members, the company operates in seven European countries and serves clients in an additional 23 countries through certified dealers. NEXUS AG's growth is evidenced by its expanding customer base and consistently increasing revenues and profits.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

NEXUS AG reported a significant increase in revenue for the first nine months of 2024, reaching KEUR 190,805, which represents an 11.4% growth compared to the same period in 2023. This growth was driven by strong performance across various segments, including NEXUS / DE, NEXUS / DIS, and NEXUS / ROE, with notable increases of 12.6%, 29.1%, and 4.3% respectively.

International Sales

The company also saw a substantial rise in international sales, which grew by 18.7% to KEUR 107,423. This increase highlights NEXUS AG's expanding presence in foreign markets and its ability to capitalize on international opportunities despite challenging economic conditions.

Profitability Improvements

NEXUS AG's profitability metrics showed impressive improvements in the third quarter of 2024. EBITDA increased by 15.2% to KEUR 40,856, while EBITA and EBIT rose by 19.4% and 21.6% respectively. These figures underscore the company's effective cost management and operational efficiency.

Earnings Per Share

The earnings per share for NEXUS AG saw a notable increase of 15.7%, rising from EUR 1.02 in the first nine months of 2023 to EUR 1.18 in the same period of 2024. This growth reflects the company's strong financial performance and its ability to deliver value to shareholders.

Positive Outlook

Looking ahead, NEXUS AG remains optimistic about its future prospects. The company anticipates continued growth driven by ongoing digitization projects in healthcare and the integration of AI functionalities into its software. NEXUS AG is committed to investing in innovation and expanding its market presence, positioning itself strongly for future success.

Summarized from source with an LLMView Source

Key figures

23.9%1Y

31.7%3Y

161%5Y

Performance

41.5%1Y

37.5%3Y

38.0%5Y

Volatility